BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Infographics: Dynamic digital data analysis
Trump administration impacts
Biopharma M&A scorecard
BioWorld 2024 review
BioWorld MedTech 2024 review
BioWorld Science 2024 review
Women's health
China's GLP-1 landscape
PFA re-energizes afib market
China CAR T
Alzheimer's disease
Israel
Rise of obesity
Radiopharmaceuticals
Biosimilars
Aging
IVDs on the rise
Coronavirus
Artificial intelligence
BioWorld. Link to homepage.
Sign In
Sign Out
My Account
Subscribe
BioWorld - Tuesday, March 11, 2025
See today's BioWorld MedTech
Home
» A second ‘rayze’: Rayzebio closes $105M series B for preclinical radiopharmaceutical pipeline
To read the full story,
subscribe
or
sign in
.
A second ‘rayze’: Rayzebio closes $105M series B for preclinical radiopharmaceutical pipeline
Dec. 10, 2020
By
Cormac Sheridan
No Comments
Rayzebio Inc. has swiftly followed up its recent $45 million series A round with a $105 million series B round that attracted several top-tier crossover investors.
BioWorld MedTech
Financings
Medical devices and technologies
Cancer
Series B